

Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)

Technology appraisal guidance

Published: 20 February 2019

[nice.org.uk/guidance/ta560](https://www.nice.org.uk/guidance/ta560)

Contents

Advice	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer because no evidence submission was received from Roche. The company has confirmed that it does not intend to make a submission because the technology is unlikely to be used at this point in the treatment pathway and is unlikely to be a cost-effective use of NHS resources.

Information

If NHS organisations wish to consider bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-3278-8

Accreditation

